# MEKanistic Therapeutics, Inc.: Phase 1 study in Solid Tumors (Phase 1), HNSCC (71 participants)

**Score:** 50/100

| Field | Value |
|---|---|
| Sponsor | MEKanistic Therapeutics, Inc. |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | MTX-531-001 Phase 1 Study in Advanced Solid Tumors |
| NCT ID | NCT07874880 |
| Phase | Phase 1 |
| Status | not yet recruiting |
| Conditions | Solid Tumors (Phase 1); HNSCC; Endometrial Cancer; Her2-negative Metastatic Breast Cancer; Pan-RAS and BRAF Wild-type Advanced; Metastatic Colorectal Cancer (CRC) |
| Intervention types | drug |
| Target enrollment | 71 |
| Site countries | United States |
| Posted | 2026-10-15 |
| Planned start | 2026-10-20 |
| Event | Newly registered study |
| Event date | 2026-10-15 |

## Why this score
- Industry sponsor (buys outsourced services).
- Not yet recruiting: vendors still being chosen.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07874880). Last refreshed: 2026-11-05T08:46:16.625Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.